Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
|
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [21] Factor VIII Products and Inhibitor Development in Severe Hemophilia A
    Gouw, Samantha C.
    van der Bom, Johanna G.
    Ljung, Rolf
    Escuriola, Carmen
    Cid, Ana R.
    Claeyssens-Donadel, Segolene
    van Geet, Christel
    Kenet, Gili
    Makipernaa, Anne
    Molinari, Angelo Claudio
    Muntean, Wolfgang
    Kobelt, Rainer
    Rivard, George
    Santagostino, Elena
    Thomas, Angela
    van den Berg, H. Marijke
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03): : 231 - 239
  • [22] Factor VIII Products and Inhibitors in Severe Hemophilia A REPLY
    van den Berg, H. Marijke
    Gouw, Samantha C.
    van der Bom, Johanna G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15): : 1457 - 1457
  • [23] Hemodialysis in a patient with severe hemophilia A and factor VIII inhibitor
    Gopalakrishnan, Natarajan
    Usha, Thiruvengadam
    Thopalan, Balasubramaniyan
    Dhanapriya, Jeyachandran
    Dineshkumar, Thanigachalam
    Thirumalvalavan, Kaliaperumal
    Sakthirajan, Ramanathan
    HEMODIALYSIS INTERNATIONAL, 2016, 20 (04) : E11 - E13
  • [24] Factor VIII haplotypes in severe hemophilia A patients in India
    Patricia Pinto
    Kanjaksha Ghosh
    Shrimati Shetty
    Annals of Hematology, 2013, 92 : 999 - 1000
  • [25] Factor VIII haplotypes in severe hemophilia A patients in India
    Pinto, Patricia
    Ghosh, Kanjaksha
    Shetty, Shrimati
    ANNALS OF HEMATOLOGY, 2013, 92 (07) : 999 - 1000
  • [26] Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
    Christiane Dobbelstein
    Georgios Leandros Moschovakis
    Andreas Tiede
    Annals of Hematology, 2020, 99 : 2105 - 2112
  • [27] Population pharmacokinetic Model of recombinant single-chain factor VIII (rVIII SingleChain) in patients with hemophilia A
    Zhang, Ying
    Roberts, John
    Bensen-Kennedy, Debra
    Veldman, Alex
    St Ledger, Katie
    Sidhu, Jagdev
    HAEMOPHILIA, 2016, 22 : 99 - 100
  • [28] Population pharmacokinetic model of recombinant single-chain factor VIII (rVIII singlechain) in patients with hemophilia A
    Zhang, Y.
    Limsakun, T.
    Bensen-Kennedy, D.
    Veldman, A.
    Sidhu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 595 - 595
  • [29] A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients
    Hazendonk, Hendrika
    Fijnvandraat, Karin
    Lock, Janske
    Driessens, Mariette
    van der Meer, Felix
    Meijer, Karina
    Kruip, Marieke
    Laros-van Gorkom, Britta
    Peters, Marjolein
    de Wildt, Saskia
    Leebeek, Frank
    Cnossen, Marjon
    Mathot, Ron
    HAEMATOLOGICA, 2016, 101 (10) : 1159 - 1169
  • [30] Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A
    Yada, Koji
    Nogami, Keiji
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024,